IRCCS San Martino-IST-National Cancer Research Institute and University, Lrago Rosanna Benzi 10, 16132 Genoa, Italy.
Anticancer Res. 2013 Feb;33(2):655-60.
To evaluate the feasibility and outcomes of stereotactic body radiotherapy (SBRT) by helical tomotherapy (HT) for patients with primary or secondary lung cancer.
Between March 2009 and January 2012, 56 patients were selected as candidates for the study and were divided into two subgroups. The ablative SBRT group included 27 patients with T1-T2 non-small cell lung cancer who received four to five large-dose fractions in two weeks and the palliative SBRT group included 29 patients with lung metastases treated with eight lower-dose fractions in four weeks.
No differences in acute toxicities were found between different fractionation schemes with different overall treatment times. Actuarial local control at 24 months was better for the ablative group (69.6%) than for the palliative one (40.4%) (p=0.0019).
HT-based SBRT was feasible and well-tolerated. Local control was satisfactory for patients treated with ablative SBRT but unsatisfactory for those treated with palliative SBRT. Outcomes also suggest the use of ablative SBRT fractionation for palliative intent.
评估立体定向体部放疗（SBRT）联合螺旋断层放疗（HT）治疗原发性或继发性肺癌的可行性和结果。
2009 年 3 月至 2012 年 1 月期间，56 名患者被选为研究对象，并分为两组。根治性 SBRT 组包括 27 名 T1-T2 期非小细胞肺癌患者，接受 4-5 次大剂量分割，2 周内完成；姑息性 SBRT 组包括 29 名肺转移瘤患者，接受 8 次低剂量分割，4 周内完成。
不同分割方案和总治疗时间的急性毒性无差异。24 个月时，根治性组的局部控制率（69.6%）优于姑息性组（40.4%）（p=0.0019）。
HT 引导的 SBRT 是可行的，且耐受性良好。根治性 SBRT 可获得满意的局部控制，但姑息性 SBRT 控制效果不佳。结果还提示采用根治性 SBRT 分割治疗具有姑息性意图。
